此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older

2026年11月9日 更新者:Sanofi

A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older

The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60 years of age and older. Placebo will be coadministered in the IIV-HD + NVXC19 study group to control for the number of injections and to maintain observer-blinding. Thus, each participant will receive 2 injections at enrollment, one in each deltoid muscle.

Study details include:

  • The study duration will be approximately 12 months per participant
  • Study intervention will be administered via a single IM injection into the right and left deltoid muscles on day (D)01

研究概览

研究类型

介入性

注册 (估计的)

6000

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Trial Transparency email recommended (Toll free for US & Canada)
  • 电话号码:option 6 800-633-1610
  • 邮箱:Contact-US@sanofi.com

学习地点

    • Lower Silesian Voivodeship
      • Wroclaw、Lower Silesian Voivodeship、波兰、50-088
        • 招聘中
        • Investigational Site Number : 6160002
    • Pomeranian Voivodeship
      • Gdynia、Pomeranian Voivodeship、波兰、81-384
        • 招聘中
        • Investigational Site Number : 6160020

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

60年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion criteria

Inclusion criteria to be checked at Screening Visit:

  • Aged 60 years or older on the day of inclusion
  • Informed consent form has been signed and dated
  • Able to attend all scheduled visits and to comply with all study procedures
  • Participant must be able to receive an injection in the deltoid muscle of both arms
  • Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine Inclusion criteria to be checked at Visit 1 (D01)
  • Aged 60 years or older on the day of inclusion
  • Participants who are healthy or with pre-existing stable condition, as determined by medical evaluation including medical history and physical examination
  • Non-childbearing potential (i.e., post-menopausal for at least 1 year or surgically sterile)
  • lnformed consent form has been signed and dated
  • Able to attend all scheduled visits and to comply with all study procedures
  • Participant must be able to receive an injection in the deltoid muscle of both arms
  • Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine

Exclusion criteria Exclusion Criteria to be Checked at Screening Visit and at Visit 1 (D01) Medical conditions

  • Known/suspected immunodeficiency; immunosuppressive therapy in past 6 months; long-term systemic corticosteroids
  • Known systemic hypersensitivity to any study intervention components or history of life-threatening reaction to study interventions or products with the same substances
  • Self-reported thrombocytopenia, contraindicating intramuscular injection, based on investigator's judgment
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection, based on investigator's judgment
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate/severe acute illness/infection (per investigator judgment)/fever (≥38.0°C [≥100.4°F]) on study intervention day. Include participant only after the condition or fever has resolved.
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
  • History of serious adverse reaction to any influenza or COVID-19 vaccines per investigator's judgment
  • Personal or family history of Guillain-Barré syndrome
  • Prior history of myocarditis, pericarditis, or myopericarditis Prior/concomitant therapy
  • Any vaccine given within 4 weeks before or within 4 weeks after study intervention
  • Previous vaccination against influenza (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of influenza infection in the previous 6 months
  • Previous vaccination against COVID-19 (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of COVID-19 infection in the previous 6 months
  • Has received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months Other exclusion
  • Deprived of freedom by an administrative or court order, or being in an emergency setting, or hospitalized involuntarily
  • Is an investigator, investigator/study center employee, or immediate family member (parent, spouse, natural/adopted child) of the investigator/employee with direct involvement in the study The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
有源比较器:Group 1, IIV-HD and EU-licensed NVXC19

IIV-HD and NVXC19 co-administered in opposite deltoid muscles

Pharmaceutical form: Suspension

Route of administration:

Intramuscular injection

Pharmaceutical form: Dispersion Route of administration: Intramuscular injection

实验性的:Group 2, IIV-HD + NVXC19 combination and placebo

IIV-HD + NVXC19 and Placebo co-administered in opposite deltoid muscles

Pharmaceutical form: Suspension Route of administration: Intramuscular injection

Pharmaceutical form: Solution Route of administration: Intramuscular injection

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Antibody titers against for each of the 3 influenza vaccine strains(in a subset of participants)
大体时间:At Day 28 after vaccination

Geometric mean (GMT) of antibody titers measured by hemagglutination inhibition (HAI)

At Day 28 after vaccination
Antibody titers against SARS-CoV-2 specific variant(in a subset of participants)
大体时间:At Day 28 after vaccination

Geometric mean (GMT) of antibody titers measured by pseudovirus neutralization test (PNT)

At Day 28 after vaccination

次要结果测量

结果测量
措施说明
大体时间
Presence of solicited injection site reactions for 8 days, including the day of vaccination (Main subset of participants)
大体时间:Up to 8 each days after vaccination

Number of participants with solicited injection site reactions pre-listed in the participant diary and case report form (CRF)

Up to 8 each days after vaccination
Presence of solicited systemic reactions for 8 days, including the day of vaccination (Main subset of participants)
大体时间:Up to 8 each days after vaccination

Number of participants with solicited systemic reactions pre-listed in the participant diary and case report form (CRF)

Up to 8 each days after vaccination
Presence of immediate adverse events after vaccination
大体时间:Within the 30 minutes after vaccination

Number of participants with immediate adverse events (AEs). Immediate adverse events are any unsolicited systemic adverse events within 30 minutes after vaccination

Within the 30 minutes after vaccination
Presence of unsolicited adverse events
大体时间:Up to 28 days after vaccination

Number of participants with unsolicited adverse events (AEs) for 28 days, including the day of vaccination

Up to 28 days after vaccination
Presence of all medically attended adverse events
大体时间:Up to 180 days after vaccination

Number of participants with medical attended adverse events (MAAEs) for 180 days, including the day of vaccination

Up to 180 days after vaccination
Presence of related medically attended adverse events linked to predefined potential immune-mediated diseases
大体时间:From Day 181 through 12 months following study vaccination

Number of participants with medical attended adverse events (MAAEs) linked to predefined potential immune-mediated diseases (PIMDs) following the study vaccination

From Day 181 through 12 months following study vaccination
Presence of all adverse events of special interest
大体时间:Up to 180 days after vaccination

Number of participants with adverse events of special interest (AESIs) for 180 days, including the day of vaccination

Up to 180 days after vaccination
Presence of all serious adverse events
大体时间:Up to 180 days after vaccination

Number of participants with serious adverse events (SAEs) for 180 days, including the day of vaccination

Up to 180 days after vaccination
Presence of related serious adverse events
大体时间:From Day 181 through 12 months following study vaccination

Number of participants with serious adverse events (SAEs) from D181 through 12 months following the last study vaccination

From Day 181 through 12 months following study vaccination
Presence of related adverse events of special interest
大体时间:From Day 181 through 12 months following study vaccination

Number of participants with adverse events of special interest (AESIs) from D181 through 12 months following the last study vaccination

From Day 181 through 12 months following study vaccination
Presence of related medical attended adverse events linked to predefined potential immune-mediated diseases that meet the criteria for serious adverse events
大体时间:From Day 181 through 12 months following study vaccination

Number of patients with medical attended adverse events (MAAES) linked to predefined potential immune-mediated diseases (PIMDs) meets criteria for serious adverse events (SAEs) from D181 through 12 months following the last study vaccination

From Day 181 through 12 months following study vaccination
Presence of adverse events leading to study discontinuation throughout the study
大体时间:From Day 01 through 12 months

Number of participants with adverse events lead to study discontinuation

From Day 01 through 12 months
Influenza seroconversion status after vaccination for each of the 3 influenza vaccine strains
大体时间:At Day 29

Percentage of participants Seroconversion is defined by: pre-injection antibody titer < 10 [1/dil] at D01 and post-injection antibody titer ≥ 40 [1/dil] at D29, or pre-injection antibody titer ≥ 10 [1/dil] at D01 and a ≥ 4-fold increase in titer at D29

At Day 29
SARS-CoV-2 seroresponse status after vaccination
大体时间:At Day 29

Percentage of participantsSeroresponse to SARS-CoV-2 is defined by: pre-injection antibody titer < LLOQ [1/dil] and post-injection antibody titer ≥ 4*LLOQ [1/dil] at D29, or pre-injection antibody titer ≥ LLOQ [1/dil] at D01 and a ≥ 4-fold increase in titer [1/dil] at D29

At Day 29
Neutralizing antibody titers measured by neutralization test (NT) against each of the 3 influenza vaccine strains before and after vaccination (in a subset of participants)
大体时间:At Day 01 and Day 29

Neutralizing antibody titers [1/dil]

At Day 01 and Day 29
Individual neutralizing antibody titer ratio measured by neutralization test NT against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
大体时间:At Day 01 and Day 29

Individual neutralizing titers ratio Day 29/Day 01

At Day 01 and Day 29
Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination(in a subset of participants)
大体时间:At Day 29

Percentage of participants with neutralization test (NT) titer ≥ 10 (1/dil)

At Day 29
Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
大体时间:At Day 29

Percentage of participants with neutralization test (NT) titer ≥ 20 (1/dil)

At Day 29
Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
大体时间:At Day 29

Percentage of participants with neutralization test (NT) titer ≥ 40 (1/dil)

At Day 29
Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
大体时间:At Day 29

Percentage of participants with neutralization test (NT) titer ≥ 80 (1/dil)

At Day 29
Fold increase in neutralization test antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
大体时间:At Day 29

Percentage of participants fold increase is defined in neutralization test (NT) antibody titer [post/pre] ≥ 2-fold rise from Day 01 to Day 29

At Day 29
Fold increase in neutralization test antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
大体时间:At Day 29

Percentage of participants fold increase is defined in neutralization test (NT) antibody titer [post/pre] ≥ 4-fold rise from Day 01 to Day 29

At Day 29

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月28日

初级完成 (估计的)

2027年12月28日

研究完成 (估计的)

2027年12月28日

研究注册日期

首次提交

2026年10月15日

首先提交符合 QC 标准的

2026年10月15日

首次发布 (实际的)

2026年10月22日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • VBT00004
  • 2026-526221-18 (注册表标识符:CTIS EU)
  • U1111-1332-8880 (注册表标识符:WHO)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅